Relay's Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed.  The company's initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.